{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:04:10Z","timestamp":1790114650903,"version":"4.0.1"},"reference-count":48,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100001316","name":"Abbott Laboratories","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001316","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinejcf.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiac Failure"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.cardfail.2024.07.024","type":"journal-article","created":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T19:30:00Z","timestamp":1723836600000},"page":"1489-1495","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Antithrombotic Strategies With Left Ventricular Assist Devices"],"prefix":"10.1016","volume":"30","author":[{"given":"MAJA","family":"CIKES","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MELANA","family":"YUZEFPOLSKAYA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"FINN","family":"GUSTAFSSON","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8683-7044","authenticated-orcid":false,"given":"MANDEEP R.","family":"MEHRA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cardfail.2024.07.024_bib0001","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1001\/jama.2022.16197","article-title":"Five-year outcomes in patients with fully magnetically levitated vs axial-flow left ventricular assist devices in the MOMENTUM 3 randomized trial","volume":"328","author":"Mehra","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.cardfail.2024.07.024_bib0002","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1093\/eurheartj\/ehad658","article-title":"Fully magnetically centrifugal left ventricular assist device and long-term outcomes: the ELEVATE registry","volume":"45","author":"Schmitto","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2024.07.024_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.healun.2024.04.065","article-title":"An ISHLT consensus statement on strategies to prevent and manage hemocompatibility related adverse events in patients with a durable, continuous-flow ventricular assist device","author":"Hollis","year":"2024","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.cardfail.2024.07.024_bib0004","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.pcad.2020.09.003","article-title":"Mechanical circulatory support devices in advanced heart failure: 2020 and beyond","volume":"63","author":"Vieira","year":"2020","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.cardfail.2024.07.024_bib0005","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/0003-4975(96)00750-3","article-title":"Low thromboembolic risk without anticoagulation using advanced-design left ventricular assist devices","volume":"62","author":"Slater","year":"1996","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.cardfail.2024.07.024_bib0006","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.healun.2019.02.009","article-title":"Prothrombotic activity of cytokine-activated endothelial cells and shear-activated platelets in the setting of ventricular assist device support","volume":"38","author":"Apostoli","year":"2019","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.cardfail.2024.07.024_bib0007","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1002\/ejhf.2275","article-title":"Aspirin and left ventricular assist devices rationale and design for the International Randomized, Placebo-Controlled, Non-Inferiority ARIES HM3 Trial","volume":"23","author":"Mehra","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2024.07.024_bib0008","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1016\/j.jacc.2021.08.047","article-title":"Matrix-degrading enzyme expression and aortic fibrosis during continuous-flow left ventricular mechanical support","volume":"78","author":"Ambardekar","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2024.07.024_bib0009","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.cardfail.2021.06.003","article-title":"Left ventricular assist devices at the crossroad of innovation in advanced heart failure","volume":"27","author":"Mehra","year":"2021","journal-title":"J Card Fail"},{"key":"10.1016\/j.cardfail.2024.07.024_bib0010","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/MAT.0000000000000388","article-title":"Design rationale and preclinical evaluation of the HeartMate 3 left ventricular assist system for hemocompatibility","volume":"62","author":"Bourque","year":"2016","journal-title":"ASAIO J"},{"key":"10.1016\/j.cardfail.2024.07.024_bib0011","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1161\/CIRCULATIONAHA.117.028303","article-title":"Hemocompatibility-related outcomes in the MOMENTUM 3 trial at 6 months: a randomized controlled study of a fully magnetically levitated pump in advanced heart failure","volume":"135","author":"Uriel","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2024.07.024_bib0012","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/j.jacc.2009.02.048","article-title":"Severely impaired von Willebrand factor-dependent platelet aggregation in patients with a continuous-flow left ventricular assist device (HeartMate II)","volume":"53","author":"Klovaite","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2024.07.024_bib0013","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/jocs.14062","article-title":"The association between novel clinical factors and gastrointestinal bleeding among patients supported with continuous-flow left ventricular assist device therapy","volume":"34","author":"Thohan","year":"2019","journal-title":"J Card Surg"},{"key":"10.1016\/j.cardfail.2024.07.024_bib0014","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.healun.2017.12.017","article-title":"Limited usefulness of endoscopic evaluation in patients with continuous-flow left ventricular assist devices and gastrointestinal bleeding","volume":"37","author":"Axelrad","year":"2018","journal-title":"J Heart Lung Transplant"},{"issue":"4","key":"10.1016\/j.cardfail.2024.07.024_bib0015","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.healun.2023.11.016","article-title":"Gastrointestinal bleeding following Heartmate 3 left ventricular assist device implantation: The Michigan Bleeding Risk Model","volume":"43","author":"Hammer","year":"2024","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.cardfail.2024.07.024_bib0016","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1161\/CIRCULATIONAHA.115.019692","article-title":"Elevated angiopoietin-2 level in patients with continuous-flow left ventricular assist devices leads to altered angiogenesis and is associated with higher nonsurgical bleeding","volume":"134","author":"Tabit","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2024.07.024_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchf.2016.08.005","article-title":"Association of nasal mucosal vascular alterations, gastrointestinal arteriovenous malformations, and bleeding in patients with continuous-flow left ventricular assist devices","volume":"4","author":"Patel","year":"2016","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cardfail.2024.07.024_bib0018","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1097\/MAT.0000000000001942","article-title":"Association of angiopoetin-2 and TNF-\u03b1 with bleeding during left ventricular assist device support: analysis from the PREVENT Biorepository","volume":"69","author":"Kim","year":"2023","journal-title":"ASAIO J"},{"key":"10.1016\/j.cardfail.2024.07.024_bib0019","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.118.005082","article-title":"Omega-3 therapy is associated with reduced gastrointestinal bleeding in patients with continuous-flow left ventricular assist device","volume":"11","author":"Imamura","year":"2018","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cardfail.2024.07.024_bib0020","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.118.004899","article-title":"Digoxin is associated with a decreased incidence of angiodysplasia-related gastrointestinal bleeding in patients with continuous-flow left ventricular assist devices","volume":"11","author":"Vukelic","year":"2018","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cardfail.2024.07.024_bib0021","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.118.005094","article-title":"Optimal hemodynamics during left ventricular assist device support are associated with reduced readmission rates","volume":"12","author":"Imamura","year":"2019","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cardfail.2024.07.024_bib0022","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1177\/03913988211013366","article-title":"Impact of heart failure drug therapy on rates of gastrointestinal bleeding in LVAD recipients: An INTERMACS analysis","volume":"44","author":"Jennings","year":"2021","journal-title":"Int J Artif Organs"},{"key":"10.1016\/j.cardfail.2024.07.024_bib0023","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1097\/MAT.0000000000001688","article-title":"Effect of angiotensin II antagonism on gastrointestinal bleeding in patients with left ventricular assist devices: a systematic review and meta-analysis","volume":"68","author":"Mahmoud","year":"2022","journal-title":"ASAIO J"},{"key":"10.1016\/j.cardfail.2024.07.024_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2021.100835","article-title":"Primary and secondary prevention strategies for gastrointestinal bleeding in patients with left ventricular assist device: a systematic review and network meta-analysis","volume":"46","author":"Rai","year":"2021","journal-title":"Curr Probl Cardiol"},{"key":"10.1016\/j.cardfail.2024.07.024_bib0025","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.healun.2010.01.011","article-title":"HeartMate II Clinical Investigators. Clinical management of continuous-flow left ventricular assist devices in advanced heart failure","volume":"29","author":"Slaughter","year":"2010","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.cardfail.2024.07.024_bib0026","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1161\/CIRCULATIONAHA.111.058412","article-title":"Use of an intrapericardial, continuous-flow, centrifugal pump in patients awaiting heart transplantation","volume":"125","author":"Aaronson","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2024.07.024_bib0027","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.healun.2015.06.018","article-title":"Safety of reduced anti-thrombotic strategies in HeartMate II patients: A one-year analysis of the US-TRACE Study","volume":"34","author":"Katz","year":"2015","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.cardfail.2024.07.024_bib0028","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.athoracsur.2016.07.072","article-title":"Outcomes in HeartMate II Patients With No Antiplatelet Therapy: 2-Year Results From the European TRACE Study","volume":"103","author":"Netuka","year":"2017","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.cardfail.2024.07.024_bib0029","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1111\/aor.14742","article-title":"Aspirin resistance in patients with ventricular assist devices: A follow-up study","volume":"48","author":"Flieder","year":"2024","journal-title":"Artif Organs"},{"key":"10.1016\/j.cardfail.2024.07.024_bib0030","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.healun.2020.05.003","article-title":"PREVENTion of non-surgical bleeding by management of HeartMate II patients without anti-platelet therapy (PREVENT II) trial","volume":"39","author":"Jorde","year":"2020","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.cardfail.2024.07.024_bib0031","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.healun.2021.02.010","article-title":"Clinical outcomes and healthcare expenditures in the real world with left ventricular assist devices \u2014 The CLEAR-LVAD study","volume":"40","author":"Pagani","year":"2021","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.cardfail.2024.07.024_bib0032","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.athoracsur.2023.11.004","article-title":"The Society of Thoracic Surgeons Intermacs 2023 Annual Report: Focus on Magnetically Levitated Devices","volume":"117","author":"Jorde","year":"2024","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.cardfail.2024.07.024_bib0033","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.healun.2020.03.001","article-title":"Effect of aspirin dose on hemocompatibility-related outcomes with a magnetically levitated left ventricular assist device: An analysis from the MOMENTUM 3 study","volume":"39","author":"Saeed","year":"2020","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.cardfail.2024.07.024_bib0034","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1001\/jama.2023.23204","article-title":"Aspirin and hemocompatibility events with a left ventricular assist device in advanced heart failure: the ARIES-HM3 randomized clinical trial","volume":"330","author":"Mehra","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.cardfail.2024.07.024_bib0035","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.1016\/j.healun.2024.02.125","article-title":"Impact of concomitant surgical procedures in a randomized controlled trial of aspirin removal in left ventricular assist device patients \u2014 an analysis from the ARIES Trial","volume":"43","author":"Pagani","year":"2024","journal-title":"J Heart and Lung Transplant."},{"key":"10.1016\/j.cardfail.2024.07.024_bib0036","series-title":"Paper presented at: Heart Failure 2024","article-title":"Outcomes with aspirin avoidance after implantation of a Fully Magnetically Levitated LVAD in patients with coronary, cerebral or peripheral vascular disease: the ARIES-HM3 randomized clinical trial","author":"Gustafsson","year":"2024"},{"key":"10.1016\/j.cardfail.2024.07.024_bib0037","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.healun.2018.03.002","article-title":"Evaluation of low-intensity anti-coagulation with a fully magnetically levitated centrifugal-flow circulatory pump-the MAGENTUM 1 study","volume":"37","author":"Netuka","year":"2018","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.cardfail.2024.07.024_bib0038","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.healun.2019.02.013","article-title":"Low-intensity anti-coagulation using Vitamin K antagonists and Factor X activity: A validation analysis of the MAGENTUM-1 study","volume":"38","author":"Connors","year":"2019","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.cardfail.2024.07.024_bib0039","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1016\/j.healun.2023.02.132","article-title":"The Magentum 2 Study: long-term analysis of complete withdrawal of anticoagulation therapy with the Heartmate 3 LVAD","volume":"42","author":"Tucanova","year":"2023","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.cardfail.2024.07.024_bib0040","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/jocs.14352","article-title":"Long-term discontinuation of warfarin in a patient with HeartMate 3 left ventricular assist device without complication","volume":"35","author":"Fiedler","year":"2020","journal-title":"J Card Surg"},{"key":"10.1016\/j.cardfail.2024.07.024_bib0041","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1016\/j.healun.2024.02.092","article-title":"Impact of Vitamin K antagonist therapy on outcomes in a randomized controlled trial of aspirin removal in LVAD patients: a prespecified analysis from the ARIES Trial","volume":"43","author":"Connors","year":"2024","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.cardfail.2024.07.024_bib0042","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1161\/CIRCULATIONAHA.109.856120","article-title":"The first evaluation of a novel vitamin K antagonist, tecarfarin (ATI-5923), in patients with atrial fibrillation","volume":"120","author":"Ellis","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2024.07.024_bib0043","unstructured":"Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts [Internet]. Accessed Jun 14, 2024.https:\/\/www.prnewswire.com\/news-releases\/cadrenal-therapeutics-receives-fda-orphan-drug-designation-for-tecarfarin-for-prevention-of-thromboembolism-and-thrombosis-in-patients-with-lvads-rvads-biventricular-assist-devices-and-total-artificial-hearts-30211."},{"key":"10.1016\/j.cardfail.2024.07.024_bib0044","article-title":"Increased thromboembolic events with dabigatran compared with Vitamin K antagonism in left ventricular assist device patients: a randomized controlled pilot trial","volume":"10","author":"Andreas","year":"2017","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cardfail.2024.07.024_bib0045","article-title":"Evaluation of the hemocompatibility of the direct oral anticoagulant apixaban in left ventricular assist devices: the DOAC LVAD Study","author":"Shah","year":"2024","journal-title":"J Am Coll Cardiol HF"},{"key":"10.1016\/j.cardfail.2024.07.024_bib0046","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCULATIONAHA.124.069726","article-title":"A prospective randomized trial of direct oral anticoagulant therapy with a fully magnetically levitated LVAD: The DOT-HM3 Study","author":"Netuka","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2024.07.024_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.cardfail.2024.05.005","article-title":"Direct oral anticoagulant therapy with a fully magnetically levitated LVAD and Bridging to Heart Transplantation: A DOT-HM3 Study Analysis","author":"Netuka","year":"2024","journal-title":"J Card Fail"},{"key":"10.1016\/j.cardfail.2024.07.024_bib0048","first-page":"1333","article-title":"Contemporary left ventricular assist device therapy as a bridge or alternative to transplantation","volume":"108","author":"Boulet","year":"2024","journal-title":"Transplantation"}],"container-title":["Journal of Cardiac Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107191642400318X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107191642400318X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T04:48:21Z","timestamp":1731386901000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S107191642400318X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":48,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S107191642400318X"],"URL":"https:\/\/doi.org\/10.1016\/j.cardfail.2024.07.024","relation":{},"ISSN":["1071-9164"],"issn-type":[{"value":"1071-9164","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antithrombotic Strategies With Left Ventricular Assist Devices","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiac Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cardfail.2024.07.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}